AB1056
Anti-Adenovirus Antibody
Chemicon®, from goat
Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)
About This Item
UNSPSC kód:
12352203
eCl@ss:
32160702
NACRES:
NA.41
klón:
polyclonal
application:
ELISA
IF
IHC
WB
IF
IHC
WB
faj reaktivitás:
human
technika/technikák:
ELISA: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
western blot: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
western blot: suitable
citations:
34
Javasolt termékek
biológiai forrás
goat
Minőségi szint
antitest forma
purified antibody
antitest terméktípus
primary antibodies
klón
polyclonal
faj reaktivitás
human
gyártó/kereskedő neve
Chemicon®
technika/technikák
ELISA: suitable
immunofluorescence: suitable
immunohistochemistry: suitable
western blot: suitable
kiszállítva
wet ice
Egyediség
Adenovirus, hexon assembly. No cross-reactivity with Para 1-3, Influenza A & B or RSV. Non reactive with HEp-2 cells.
Immunogén
Hexon from adenovirus type 5.
Alkalmazás
ELISA: >1:5,000
Fluorescence microscopy, indirect.
Immunoblotting: unboiled samples in 1mM DTT and 2% SDS only
Immunohistochemistry
Optimal working dilutions must be determined by end user
Fluorescence microscopy, indirect.
Immunoblotting: unboiled samples in 1mM DTT and 2% SDS only
Immunohistochemistry
Optimal working dilutions must be determined by end user
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
This Anti-Adenovirus Antibody is validated for use in ELISA, IF, WB, IH for the detection of Adenovirus.
Fizikai forma
Format: Purified
IgG fraction (>95% pure). In PBS (0.01 M, pH 7.2) with 0.1% sodium azide
Tárolás és stabilitás
Maintain at -20° in undiluted aliquots for up to 12 months after date of receipt. Avoid repeated freeze/thaw cycles.
Egyéb megjegyzések
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Jogi információk
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Jogi nyilatkozat
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Nem találja a megfelelő terméket?
Próbálja ki a Termékválasztó eszköz. eszközt
Tárolási osztály kódja
12 - Non Combustible Liquids
WGK
WGK 2
Lobbanási pont (F)
Not applicable
Lobbanási pont (C)
Not applicable
Analitikai tanúsítványok (COA)
Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.
Már rendelkezik ezzel a termékkel?
Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.
Lynette M Phillips et al.
Neuro-oncology, 23(11), 1911-1921 (2021-06-02)
Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that
Matthew Glen Robertson et al.
Molecular therapy oncolytics, 20, 659-668 (2021-04-06)
Encoding the sodium iodide symporter (NIS) by an adenovirus (Ad) is a promising strategy to facilitate non-invasive imaging and radiotherapy of pancreatic cancer. However, insufficient levels of NIS expression in tumor cells have limited its clinical translation. To optimize Ad-based
Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter.
W M Gommans, P M J McLaughlin, J A C Schalk, G M M Groothuis, H J Haisma, M G Rots
Journal of Controlled Release : Official Journal of the Controlled Release Society null
M Verónica Lopez et al.
PloS one, 4(4), e5119-e5119 (2009-04-02)
The clinical efficacy of conditionally replicative oncolytic adenoviruses (CRAd) is still limited by the inefficient infection of the tumor mass. Since tumor growth is essentially the result of a continuous cross-talk between malignant and tumor-associated stromal cells, targeting both cell
Marc Garcia-Moure et al.
Scientific reports, 9(1), 14368-14368 (2019-10-09)
Last advances in the treatment of pediatric tumors has led to an increase of survival rates of children affected by primitive neuroectodermal tumors, however, still a significant amount of the patients do not overcome the disease. In addition, the survivors
Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.
Lépjen kapcsolatba a szaktanácsadással